In a roughly 75-25 deal, Recursion Bio and Exscientia will (if the merger goes through) become one company, combining Recursion’s expertise in biology with Exscientia’s focus on chemistry.
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
After hours: December 31 at 4:01:46 PM EST Loading Chart for OTTR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback